RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0042-1743504
Case for More Autologous Transplants in Myeloma in Resource-Constrained Settings
![](https://www.thieme-connect.de/media/10.1055-s-00050348/202203/lookinside/thumbnails/10-1055-s-0042-1743504_213610534-1.jpg)
Abstract
Multiple myeloma is characterized by a near universal risk of relapse. Autologous stem cell transplantation provides a significant progression free survival benefit but is under utilized worldwide. We provide a small snapshot of why ASCT assumes greater importance in resource-constrained settings.
Publikationsverlauf
Artikel online veröffentlicht:
28. Juni 2022
© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Kristinsson SY, Landgren O, Dickman PW, Derolf AR, Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 2007; 25 (15) 1993-1999
- 2 Usui Y, Ito H, Koyanagi Y. et al. Changing trend in mortality rate of multiple myeloma after introduction of novel agents: a population-based study. Int J Cancer 2020; 147 (11) 3102-3109
- 3 Dimopoulos MA, Moreau P, Terpos E. et al; EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up† . Ann Oncol 2021; 32 (03) 309-322
- 4 Moreau P, Touzeau C. Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation. Leuk Suppl 2013; 2 (Suppl. 01) S15-S20
- 5 Mateos M-V, Cavo M, Blade J. et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 2020; 395 (10218): 132-141
- 6 Kumar S, Jacobus SJ, Cohen AD. et al. Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): results of ENDURANCE (E1A11) phase III trial. J Clin Oncol 2020; 38 (18) 3
- 7 Facon T, Kumar S, Plesner T. et al; MAIA Trial Investigators. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med 2019; 380 (22) 2104-2115
- 8 Gay F, Cerrato C, Petrucci MT. et al. Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. J Clin Oncol 2019; 37 (15) 8002-8002
- 9 Attal M, Lauwers-Cances V, Hulin C. et al; IFM 2009 Study. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med 2017; 376 (14) 1311-1320
- 10 Cavo M, Petrucci MT, Di Raimondo F. et al. Upfront single versus double autologous stem cell transplantation for newly diagnosed multiple myeloma: an intergroup, multicenter, phase III study of the European Myeloma Network (EMN02/HO95 MM Trial). American Society of Hematology; Washington, DC: 2016
- 11 Su B, Zhu X, Jiang Y. et al. A meta-analysis of autologous transplantation for newly diagnosed multiple myeloma in the era of novel agents. Leuk Lymphoma 2019; 60 (06) 1381-1388
- 12 Dhakal B, Szabo A, Chhabra S. et al. Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis. JAMA Oncol 2018; 4 (03) 343-350
- 13 Gonsalves WI, Buadi FK, Ailawadhi S. et al. Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement. Bone Marrow Transplant 2019; 54 (03) 353-367
- 14 Costa LJ, Zhang M-J, Zhong X. et al. Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myeloma. Biol Blood Marrow Transplant 2013; 19 (11) 1615-1624
- 15 Cowan AJ, Baldomero H, Atsuta Y. et al. The global state of hematopoietic stem cell transplantation for multiple myeloma: an analysis of the worldwide network of blood and marrow transplantation (WBMT) database and the Global Burden of Disease Study. Biol Blood Marrow Transplant 2020; 26 (12) 2372-2377
- 16 Kulkarni U, Devasia AJ, Korula A. et al. Clinical outcomes in multiple myeloma post-autologous transplantation-a single centre experience. Indian J Hematol Blood Transfus 2019; 35 (02) 215-222
- 17 Cowan AJ, Allen C, Barac A. et al. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol 2018; 4 (09) 1221-1227
- 18 Prinja S, Kaur G, Malhotra P. et al. Cost-effectiveness of autologous stem cell treatment as compared to conventional chemotherapy for treatment of multiple myeloma in India. Indian J Hematol Blood Transfus 2017; 33 (01) 31-40
- 19 Martino M, Paviglianiti A, Memoli M, Martinelli G, Cerchione C. Multiple myeloma outpatient transplant program in the era of novel agents: state-of-the-art. Front Oncol 2020; 10: 592487